Ann: Anteo Shareholder Presentation, page-266

https://www.asx.com.au/asxpdf/20130729/pdf/42h9b1s3hlhbtp.pdf

AFFYMETRIX/eBioscience/Thermo Fisher

We were advised that 32 new products in the ProcartaPlex range, that utilise Mix&Go were introduced to the market at the end of June. Revenues from these, and additional new products, will now begin to flow as they enter the range. The Affymetrix acquisition of eBioscience has decreased the likelihood that Mix&Go will be incorporated into all products within that range due to the better performance that is possible from the bead at the core of the ProcartaPlex range.
The work we have undertaken in collaboration with Affymetrix on a new bead-based range of products has generated positive results. Optimisation work undertaken has identified a novel protocol that presents the possibility of delivering additional gains of 3-5 fold in sensitivity. We are investigating the general nature of this protocol to assess whether it improves outcomes with all antibodies and on other surfaces.
Two further developmental projects, in areas that are distinct from our current areas of focus, remain at an early stage.

BARD1 leverages ProcartaPlex technology to accelerate development of ovarian cancer detection

BARD1 develops world-first blood test for breast cancer detection; offers high diagnostic accuracy

Hmmmmmm.........